secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0002036042-25-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna Therapeutics Q1 net loss $16.5M; cash $354.7M; Phase 1 dosing complete for two NBD1 stabilizers
--------------------------------------------------------------------------------

- Net loss of $16.5M for Q1 2025, up from $11.8M in Q1 2024; R&D expenses $13.7M vs $10.2M.
- Cash and cash equivalents $354.7M as of March 31, 2025, including $199.6M net IPO proceeds; runway into 2028.
- Phase 1 dosing completed for SION-719 and SION-451; topline data expected in Q2 2025.
- Phase 2a POC trial and at least one dual combination MAD trial on track for H2 2025; topline data mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000203604225000014/0002036042-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000203604225000014/sion-20250512.htm
  HTML page:      https://secwatch.observer/filing/0002036042-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer